Pancreatic Cancer Research

ResearcherFudan UniversityNo recent work listed

Jingxian Feng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0007-8819-7387; OpenAlex author ID A5066666349. Sources: OpenAlex.

Their work

Papers
2
Trials
0
Grants
0
Labs led
0
Collaborators
6
Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper

Papers 2

  1. Sequential delivery of nanoformulated α-mangostin and triptolide overcomes permeation obstacles and improves therapeutic effects in pancreatic cancer. Co-author DOI 10.1016/j.biomaterials.2020.119907↗
  2. Sequential Targeting TGF-β Signaling and KRAS Mutation Increases Therapeutic Efficacy in Pancreatic Cancer. Co-author DOI 10.1002/smll.201900631↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chen Liang · 2 shared papers, 2019–2020 · strength 0.18
  2. Yukun Huang · 2 shared papers, 2019–2020 · strength 0.18
  3. Jun Chen · 2 shared papers, 2019–2020 · strength 0.18
  4. Yu Chen · 1 shared paper, 2020 · strength 0.10
  5. Qian Zhang · 1 shared paper, 2019 · strength 0.08
  6. Yuanyuan Pei · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.